Vitiligo is visible. Its full impact often is not.

Vitiligo is among the most visible chronic health conditions. But for people living with the condition, what is visible on the skin tells only part of the story.

That distinction was at the center of City & State’s recent Health Equity Forum: Vitiligo Awareness, Access & Action, which brought together policymakers, patient advocates and medical experts for a conversation about how vitiligo is understood, how it affects patients and where barriers to care remain.

For decades, vitiligo was often viewed primarily through the lens of appearance because of its most recognizable symptom: the loss of skin pigmentation. Medical understanding of the condition, however, has advanced considerably.

Vitiligo is a chronic autoimmune condition. It occurs when the immune system mistakenly targets melanocytes, the cells responsible for producing pigment in the skin. The resulting depigmented patches may be its most visible manifestation, but they reflect an underlying biological process.

That matters because the way a medical condition is characterized can shape how people living with it are perceived, whether they seek treatment and how the healthcare system responds to their needs.

“Describing vitiligo as cosmetic does not reflect the medical reality of this condition,” David Brooks, group vice president and head of global medical affairs at Incyte, said in remarks opening the forum. “It overlooks both what is happening within the body and the burdens people may carry every day.”

Those burdens became a central part of the discussion.

Paul, Peter and Tyrone Graham, three brothers from Harlem who live with vitiligo and have used their online platform to raise awareness, spoke about their own experiences and the importance of visibility and representation. Their perspective put a human face on an issue that can too easily be discussed only in clinical terms.

Vitiligo can affect people differently, but its impact can extend well beyond changes in pigmentation. People living with vitiligo have described challenges involving self-esteem, social interactions, stigma and isolation. Some spend significant time concealing affected areas of their skin or navigating questions and assumptions from others about their appearance.

Those effects can be particularly meaningful for children and young people who are still developing their sense of identity.

Audience members added another dimension to the discussion. People living with vitiligo and parents of children with the condition raised questions about navigating resources, finding appropriate care and dealing with the mental and emotional effects of a condition that can be immediately visible to everyone around them.

The conversation also turned to health equity and the role of policymakers.

Assembly Member Landon Dais discussed the importance of access to treatment and the broader health disparities that can affect Black New Yorkers. Assembly Member Alicia Hyndman connected the discussion to her work around sickle cell disease and the broader challenge of ensuring that conditions affecting historically underserved communities receive appropriate recognition, resources and attention.

Their comments underscored a broader point: Advances in medical understanding matter only if patients can benefit from them.

Researchers and clinicians now understand far more about the immune pathways involved in vitiligo than they did decades ago, and the medical community increasingly recognizes the condition as a chronic autoimmune condition. Yet awareness does not automatically translate into access.

For patients and families, the practical questions remain straightforward: Can they find a provider who understands the condition? Can they navigate the healthcare system? Are available treatments accessible to them? And are decisions about their care rooted in medical reality rather than the outdated assumption that vitiligo is simply cosmetic?

There are no single answers to those questions, and the forum reflected the different roles that patients, advocates, clinicians, policymakers and the healthcare system will play in addressing them.

But greater understanding is an important starting point.

Vitiligo is visible. The autoimmune process behind it is not. Neither are many of the emotional, social and practical burdens carried by people living with the condition.

Closing that gap between what people see and what patients actually experience is essential to a more informed conversation about vitiligo and to ensuring that people living with it are treated with the same seriousness afforded to those with other chronic autoimmune conditions.